Double-blind, Double-dummy, Randomized Controlled Trials of Bupropion Hydrochloride Sustained-release Tablets for Depression_Chinese Journal of Evidence-Based Medicine

Authors：

WANG Xue , ZHANG Bo , SUN Xueli ,  LI Jing

Department of Mental Health, West China Hospial of Sichuan University, Chengdu 610041, China;

Corresponding author：

LI Jing, Email: wangxue73@yahoo.com.cn

Keywords：

Bupropion hydrochloride; Sustained-release tablets; Fluoxetine tablets; Depression; Therapeutic effect; Safety

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective 　To evaluate the therapeutic effect and safety of Bupropion hydrochloride sustained-release tablets in the treatment of depression.
Methods 　A total of 48 patients meeting the diagnostic criteria of depression of CCMD-3 were randomly treated with Bupropion hydrochloride sustained-release tablets or Fluoxetine tablets for 42 days. Hamilton depression rating scale, Hamilton anxiety rating scale, clinical global impression and treatment emergent symptom scale were used to evaluate the therapeutic effect. Blood routine test, urine routine test and electrocardiogram were examined before and after the treatment.
Results 　The effective rate of Bupropion hydrochloride sustained-release tablets [83% (20/ 24) ] was higher than that of Fluoxetine tablets [63% (15/ 24)], with a P value of 0.104. The incidence of adverse reactions was 46% (11/24) in both groups.
Conclusion 　The therapeutic effect of Bupropion hydrochloride sustained-release tablets on depression is similar to that of Fluoxetine tablets, with mild adverse reactions to both treatments.

Citation： WANG Xue,ZHANG Bo,SUN Xueli,LI Jing. Double-blind, Double-dummy, Randomized Controlled Trials of Bupropion Hydrochloride Sustained-release Tablets for Depression. Chinese Journal of Evidence-Based Medicine, 2007, 07(6): 409-414. doi: Copy

1.	Tomarken AJ, Dichter GS, Freid C, et al. Assessing the effects of bupropion SR on mood dimensions of depression. J Affect Disord, 2004, 78(3): 235-241.
2.	Glod CA, Lynch A, Flynn E, et al. Open trial of bupropion SR in adolescent major depression. J Child Adolesc Psychiatr Nurs, 2003, 16(3): 123-130.
3.	Jamerson BD, Krishnan KR, Roberts J, et al. Effect of bupropion SR on specific symptom clusters of depression: analysis of the 31-item Hamilton Rating Scale for depression. Psychopharmacol Bull, 2003, 37(2): 67-78.
4.	Croft H, Houser TL, Jamerson BD, et al. Effect on body weight of bupropion sustained-release in patients with major depression treated for 52 weeks. Clin Ther, 2002, 24(4): 662-672.
5.	Weihs KL, Houser TL, Batey S R, et al. Continuation phase treatment with bupropion SR effectively decreases the risk for relapse of depression. Biol Psychiatry, 2002, 51(9): 753-761.
6.	Nieuwstraten CE, Dolovich LR. Bupropion versus selective serotonin-reuptake inhibitors for treatment of depression. Ann Pharmacother, 2001, 35(12): 1608-1613.
7.	Steffens DC, Doraiswamy PM, McQuoid DR. Bupropion SR in the naturalistic treatment of elderly patients with major depression. Int J Geriatr Psychiatry, 2001, 16(9): 862-865.
8.	Weihs KL, Sette EC Jr, Batey SR, et al. Bupropion sustained release versus paroxetine for the treatment of depression in the elderly. J Clin Psychiatry, 2000, 61(3): 196-202.
9.	Daviss WB, Bentivoglio P, Racusin R, et al. Bupropion sustained release in adolescents with attention-deficit/hyperactivity disorder and depression. J Am Acad Child Adolesc Psychiatry, 2001, 40(3): 307-314.
10.	Leentjens AF, Verhey FR, Vreeling FW. Successful treatment of depression in a Parkinson disease patient with bupropion. Ned Tijdschr Geneeskd, 2000, 144(45): 2157-2159.
11.	Fatemi SH, Emamian ES, Kist DA. Venlafaxine and bupropion combination therapy in a case of treatment-resistant depression. Ann Pharmacother, 1999, 33(6): 701-703.
12.	Marshall RD, Liebowitz MR. Paroxetine/bupropion combination treatment for refractory depression. J Clin Psychopharmacol,1996, 16(1): 80-81.
13.	Apter JT, Kushner SF, Woolfolk RL. Bupropion/nortriptyline combination for refractory depression. Ann Clin Psychiatry, 1994, 6(4): 255-258.
14.	Settle EC, Stahl SM, Batey SR, et al. Safety profile of sustained-release bupropion in depression: results of three clinical trials. Clin Ther, 1999, 21(3): 454-463.

1. Tomarken AJ, Dichter GS, Freid C, et al. Assessing the effects of bupropion SR on mood dimensions of depression. J Affect Disord, 2004, 78(3): 235-241.
2. Glod CA, Lynch A, Flynn E, et al. Open trial of bupropion SR in adolescent major depression. J Child Adolesc Psychiatr Nurs, 2003, 16(3): 123-130.
3. Jamerson BD, Krishnan KR, Roberts J, et al. Effect of bupropion SR on specific symptom clusters of depression: analysis of the 31-item Hamilton Rating Scale for depression. Psychopharmacol Bull, 2003, 37(2): 67-78.
4. Croft H, Houser TL, Jamerson BD, et al. Effect on body weight of bupropion sustained-release in patients with major depression treated for 52 weeks. Clin Ther, 2002, 24(4): 662-672.
5. Weihs KL, Houser TL, Batey S R, et al. Continuation phase treatment with bupropion SR effectively decreases the risk for relapse of depression. Biol Psychiatry, 2002, 51(9): 753-761.
6. Nieuwstraten CE, Dolovich LR. Bupropion versus selective serotonin-reuptake inhibitors for treatment of depression. Ann Pharmacother, 2001, 35(12): 1608-1613.
7. Steffens DC, Doraiswamy PM, McQuoid DR. Bupropion SR in the naturalistic treatment of elderly patients with major depression. Int J Geriatr Psychiatry, 2001, 16(9): 862-865.
8. Weihs KL, Sette EC Jr, Batey SR, et al. Bupropion sustained release versus paroxetine for the treatment of depression in the elderly. J Clin Psychiatry, 2000, 61(3): 196-202.
9. Daviss WB, Bentivoglio P, Racusin R, et al. Bupropion sustained release in adolescents with attention-deficit/hyperactivity disorder and depression. J Am Acad Child Adolesc Psychiatry, 2001, 40(3): 307-314.
10. Leentjens AF, Verhey FR, Vreeling FW. Successful treatment of depression in a Parkinson disease patient with bupropion. Ned Tijdschr Geneeskd, 2000, 144(45): 2157-2159.
11. Fatemi SH, Emamian ES, Kist DA. Venlafaxine and bupropion combination therapy in a case of treatment-resistant depression. Ann Pharmacother, 1999, 33(6): 701-703.
12. Marshall RD, Liebowitz MR. Paroxetine/bupropion combination treatment for refractory depression. J Clin Psychopharmacol,1996, 16(1): 80-81.
13. Apter JT, Kushner SF, Woolfolk RL. Bupropion/nortriptyline combination for refractory depression. Ann Clin Psychiatry, 1994, 6(4): 255-258.
14. Settle EC, Stahl SM, Batey SR, et al. Safety profile of sustained-release bupropion in depression: results of three clinical trials. Clin Ther, 1999, 21(3): 454-463.

Chinese Journal of Evidence-Based Medicine

Double-blind, Double-dummy, Randomized Controlled Trials of Bupropion Hydrochloride Sustained-release Tablets for Depression

Abstract Full text Figures/Tables Video References Cited by

Format

Content